Exelixis, Inc. [EXEL]

Source: 

Company Overview

Exelixis, Inc. is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead investigational asset, zanzalintinib, currently the focus of an extensive late-stage clinical development program.